Texas Institute awards $20M grant for rare disease drug development
What happened
The Cancer Prevention and Research Institute of Texas secured $20 million in grant funding to support research and development. This funding complements the efforts of a lead drug candidate, eRapa, which is being studied for Familial Adenomatous Polyposis (FAP). The drug is an oral candidate designed to reduce the need for surgical treatments for this rare genetic disease.
From finanznachrichten.de
Why it matters
The grant funding supports the Phase 3 registrational trial of eRapa, which is currently more than 50 percent enrolled. The drug aims to treat FAP, a condition for which surgery is currently the only approved remedy.
From finanznachrichten.de
Who's involved
- Cancer Prevention and Research Institute of TexasProvided $20 million in grant funding to accelerate research and development
- Plus TherapeuticsReceives grant funding from the Institute to accelerate research and development
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
The Institute might see increased investment costs to support the Phase 3 eRapa program
Keep exploring
The entities involved
-
Cancer Prevention and Research Institute of Texas
facility in Austin, United States
Nothing else this week.